thebench.bio

Industry Daily Summary

Industry Daily Summary: What Happened on October 6, 2026

Shionogi to acquire IntraBio for $2 billion, adding rare-disease drug

Roche and CSL signed large licensing deals. Lilly expanded a research collaboration, and Pacira found a European partner.

  • Updated
  • Read from 6 articles, 2 publications

Today in brief

Shionogi plans to acquire IntraBio for $2 billion, bringing Aqneursa, an approved treatment for two rare neurological disorders, into its portfolio.12 Roche will pay Alector $100 million upfront for global rights to its preclinical Parkinson’s candidate AL050, with up to $1.17 billion in milestone payments.3 CSL agreed to pay Alentis $355 million upfront to develop lixudebart for kidney and liver diseases, with up to $1.2 billion more tied to commercial milestones.4

Shionogi to acquire IntraBio and Aqneursa for $2 billion

Shionogi announced on October 5 that it would buy IntraBio for $2 billion, gaining global rights to Aqneursa if the deal closes.12 Aqneursa is approved in the US for Niemann-Pick disease type C and ataxia-telangiectasia, and in Europe for Niemann-Pick disease type C.12

Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue.2 The company expects the acquisition to close by year-end, subject to regulatory review.2

Roche pays $100 million upfront for Alector’s Parkinson’s candidate

Roche licensed global rights to AL050, a preclinical enzyme replacement therapy designed to address GCase deficiency in Parkinson’s disease.3 Alector will receive $100 million upfront and could earn up to $1.17 billion in development, regulatory and commercial milestones.3

Genentech will lead development, manufacturing, regulatory work and commercialization across indications.3 Alector retains its ABC delivery platform, which the company says is designed to help therapies cross the blood-brain barrier.3

CSL backs Alentis’ lixudebart with $355 million upfront

CSL and Alentis will develop lixudebart for several kidney and liver diseases under an exclusive collaboration.4 CSL will pay $355 million upfront and may provide up to $1.2 billion in commercial milestones.4

Alentis is testing lixudebart in a Phase II trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis, a severe kidney condition.4 CSL will fund that program and planned Phase III work, along with Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis.4 If the drug reaches the market, Alentis is entitled to 55% of global profits.4

Also worth knowing

  • Lilly expanded its Gate Bioscience collaboration to cover one new target, with potential milestone payments of up to $870 million and an option to add another target.5

  • Pacira gave Molteni Farmaceutici exclusive rights to commercialize Exparel in the EU and UK. The companies expect the first sale in 2027.6

Also published